GtoPdb is requesting financial support from commercial users. Please see our sustainability page for more information.

APT-101   Click here for help

GtoPdb Ligand ID: 14335

Synonyms: APT101 | compound 423 [WO2017100558A1] | compound 52 [PMID: 35594649]
Compound class: Synthetic organic
Comment: APT-101 (APIE Therapeutics) is an orally bioavailable small molecule that acts as an apelin receptor (APLNR; APJ) agonist [2]. It activates the apelin/apelin receptor pathway to trigger the repair of pulmonary vascular endothelial cell breakdown that drives damage in fibrotic and sclerotic lung diseases [3,5-8].
We obtained the IUPAC descriptor for the molecule from the FDA Orphan Drug register. This chemical structure was first claimed in a patent series from RTI International [4], and is a structure match for compound 52 in [2].
2D Structure
Click here for help
Click here for structure editor
Physico-chemical Properties
Click here for help
Hydrogen bond acceptors 7
Hydrogen bond donors 2
Rotatable bonds 11
Topological polar surface area 85.24
Molecular weight 542.54
XLogP 4.32
No. Lipinski's rules broken 1

Generated using the Chemistry Development Kit (CDK) (Willighagen EL et al. Journal of Cheminformatics vol. 9:33. 2017, doi:10.1186/s13321-017-0220-4; https://cdk.github.io/)

SMILES / InChI / InChIKey
Click here for help
Canonical SMILES C1CCC(C1)N2C(=CC(=N2)C(=O)N[C@@H](CCN3CCCC(C3)(F)F)CC(=O)O)C4=C(C=CC=C4)C(F)(F)F
Isomeric SMILES C1(CCCC1)N2N=C(C=C2C3=C(C=CC=C3)C(F)(F)F)C(=O)N[C@H](CC(=O)O)CCN4CC(CCC4)(F)F
InChI InChI=1S/C26H31F5N4O3/c27-25(28)11-5-12-34(16-25)13-10-17(14-23(36)37)32-24(38)21-15-22(35(33-21)18-6-1-2-7-18)19-8-3-4-9-20(19)26(29,30)31/h3-4,8-9,15,17-18H,1-2,5-7,10-14,16H2,(H,32,38)(H,36,37)/t17-/m0/s1
InChI Key HSTYVOXQTWCRDM-KRWDZBQOSA-N

Generated using the Chemistry Development Kit (CDK) (Willighagen EL et al. Journal of Cheminformatics vol. 9:33. 2017, doi:10.1186/s13321-017-0220-4; https://cdk.github.io/)

No information available.
Summary of Clinical Use Click here for help
APT-101 was granted FDA orphan designation in 2022, to treat idiopathic pulmonary fibrosis (IPF) and systemic sclerosis [1].